Zennie Abraham / Zennie62
News

Immunotherapy with pembrolizumab deemed cost-effective for advanced melanoma in Hong Kong – EurekAlert (press release)

Immunotherapy with pembrolizumab deemed cost-effective for advanced melanoma in Hong KongEurekAlert (press release)“This is the first study to address the cost-effectiveness of checkpoint inhibitors in the management of advanced cancer in Hong Kong,” said lead author Dr Herbert Loong, Clinical Assistant Professor in the Department of Clinical Oncology of The … …read more From:: Hong […]